Voclosporin with mycophenolic acid and low-dose steroids to treat lupus nephritis Phase 3 clinical trials reach major and secondary endpoints
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Lupus nephritis is a sign of severe progression of SLE disease due to inflammation of the kidneys caused by systemic lupus erythematosus (SLE)Today, Aurinia Pharmaceuticals(http://announced that the company's development of voclosporin in combination with mycophenolic acid (MM) and low-dose steroids has reached all major endpoints and critical secondary ends in the critical Phase 3 clinicaltrial
(http://for patients with lupus nephritis (LN)significantly improving kidney remission compared to standard therapiesAbout Voclosporin
Voclosporin is a potential "best-in-class" calcium-toned neurophosphatase inhibitor (CNI)By inhibiting calcium-toned neurophosphatase, it blocks IL-2 expression and T-cell-mediated immune responses and stabilizes foot cells (podocyte) in the kidneysVoclosporin was granted fast-track eligibility by theFDA(http://in 2016The global study, involving 357 LN patients, showed that voclosporin achieved a renal respo
nse rate of 40.8 percent,compared with 22.5 percent (p0.00 http://
1) in the control group
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
